Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Infigratinib - BridgeBio Pharma/Novartis

Drug Profile

Infigratinib - BridgeBio Pharma/Novartis

Alternative Names: BBP-831; BGJ-398; BGJ-398 phosphate; Infigratinib phosphate; NVP-BGJ398

Latest Information Update: 01 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Array BioPharma; BridgeBio Pharma; Novartis; Novartis Oncology; University of Chicago
  • Class Aniline compounds; Antineoplastics; Methylurea compounds; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cholangiocarcinoma
  • Phase II Haematological malignancies; Head and neck cancer
  • Preclinical Achondroplasia
  • Discontinued Bladder cancer; Glioblastoma; Malignant melanoma; Solid tumours

Most Recent Events

  • 07 Nov 2019 BridgeBio Pharma plans the PROPEL2 phase II trial for Achondroplasia in 2020
  • 07 Nov 2019 BridgeBio Pharma announces intention to submit NDA to the US FDA for cholangiocarcinoma in 2020
  • 18 Oct 2019 Pharmacodynamics and adverse event data from a preclinical trial in Achondroplasia presented by QED Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top